Literature DB >> 17940561

[Expressions of ERCC2 and ERCC4 genes in osteosarcoma and peripheral blood lymphocytes and their clinical significance].

Xiao Li1, Wei Guo, Dan-hua Shen, Rong-li Yang, Jian Liu, Hui Zhao.   

Abstract

OBJECTIVE: To detect the expressions of ERCC2 and ERCC4 genes in osteosarcoma (OS) and peripheral blood lymphocyte (PBL), and their relationship with the prognosis to provide potential markers for evaluating the chemotherapeutic effect and prognosis of OS.
METHODS: Between Jan. 2006 and Nov. 2006, 26 OS patients were chosen for this study. A small quantity of specimens were obtained in the open biopsy before chemotherapy, as well as 5 mL venous blood to separate PBLs. All of the patients received chemotherapy preoperatively and then operation. After the operation, the resected tumor specimens were examined completely for tumor necrosis rates which were related to chemotherapy. The tumor necrosis rates were classified into two groups, high tumor necrosis (TN) group and low TN group. The expressions of ERCC2 mRNA and ERCC4 mRNA of OS cells in open biopsy specimens were analysed by real time PCR, and so were those of the PBLs from venous blood. The correlations of mRNA expression level of the two genes both in OS cells and in PBLs with different tumor necrosis groups were analysed,respectively. The correlations of ERCC2 mRNA in OS and PBLs were analyzed, and so were those of ERCC4 mRNA level. And their associations with clinical features, including sex, age, tumor volume, tumor stages, alkaline phosphatase (AKP) and lactate dehydro-genase (LDH) were analyzed , respectively. All of the data were processed statistically with SPSS software.
RESULTS: The expression levels of ERCC4 mRNA in OS cells of high TN group (6.29+/-1.20) were significantly higher compared to those of the low TN group (5.14+/-1.16), P=0.023. Also the expression levels of ERCC4 mRNA in PBLs of high TN group (5.59+/-1.15) were significantly higher compared to those of the low TN group (4.52+/-1.20), P=0.032. And there was a positive correlation between ERCC4 mRNA levels in OS and in PBLs (r=0.768, P<0.01). ERCC2 mRNA only in OS cells of high TN group (3.49+/-1.14) were significantly higher compared to those of the low TN group (2.33+/-1.31), P=0.029. ERC4 expression in OS was significantly associated with age and ERCC2 expression in OS was significantly associated with AKP level, respectively.
CONCLUSION: The expressions of ERCC4 mRNA in OS cells or PBLs and ERCC2 mRNA were correlated with chemotherapeutic effect of osteosarcoma. The detection of the genes above may be useful for evaluating prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940561

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  6 in total

1.  Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp.

Authors:  Hui Zhao; Changliang Peng; Guorui Ruan; Junlin Zhou; Yihan Li; Yong Hai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.

Authors:  Hui Zhao; Wei Guo; Changliang Peng; Tao Ji; Xinchang Lu
Journal:  Mol Biol Rep       Date:  2009-08-22       Impact factor: 2.316

3.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

Review 4.  Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.

Authors:  Louise Marchandet; Morgane Lallier; Céline Charrier; Marc Baud'huin; Benjamin Ory; François Lamoureux
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

5.  Construction of Molecular Subtype and Prognosis Prediction Model of Osteosarcoma Based on Aging-Related Genes.

Authors:  Chunli Dong; Yindi Sun; Ying Zhang; Bianni Qin; Tao Lei
Journal:  J Oncol       Date:  2022-09-16       Impact factor: 4.501

6.  A case report of primary osteosarcoma originating from kidney.

Authors:  Changkun Huang; Xuan Zhu; Wei Xiong; Xiaokun Zhao; Ran Xu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.